# APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

> **NCT04643405** · PHASE1,PHASE2 · TERMINATED · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 21 (actual)

## Conditions studied

- Advanced Pancreatic Cancer

## Interventions

- **DRUG:** APG-1387 for Injection
- **DRUG:** Gemcitabine
- **DRUG:** Nab paclitaxel

## Key facts

- **NCT ID:** NCT04643405
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-17
- **Primary completion:** 2024-06-25
- **Final completion:** 2024-12-10
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Company Strategy
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04643405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04643405, "APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04643405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*